Weekly Recap | Personalis +0.76%, SC 13E3 filing surfacesWeekly Review·Sep 5, 2026 at 07:43 AMPSNL-0.66%
The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.22%, Regenxbio decreased 14.31%, Humacyte declined 13.93%, and Anavex Life Sciences fell 8.74%. In contrast, Mesoblast rose 7.21%, Personalis increased 10.03%, Invivyd gained 10.14%, PepGen surged 17.99%, and Neumora Therapeutics jumped 25.10%Wallstreetcn·Feb 10, 2026 at 11:10 PMIDNA-0.54%RGNX-2.83%
The Nasdaq Biotechnology Index rose over 1.6%, outperforming the three major U.S. stock indices. Cabaletta Bio increased by 26.28%, Altimmune, Prime Medicine, Personalis, and Corvus Pharmaceuticals rose by 16.67%-15.21%, and GRAIL increased by 15.03%. Aardvark Therapeutics fell by 4.68%, Monte Rosa Therapeutics dropped by 4.99%, Bioage Labs decreased by 6.06%, and Legend Bio declined by 6.84%Wallstreetcn·Jan 22, 2026 at 11:21 PMPRME-9.92%BIB0.00%
The Nasdaq Biotechnology Index closed up nearly 1.4%, closely mirroring the performance of the Dow Jones Industrial Average. Among the constituent stocks, Esperion rose 16.09%, ARS Pharmaceuticals rose 15.50%, Anavex Life Sciences rose 12.34%, Personalis rose 12.31%, Autolus Therapeutics rose 12.10%, and Aura Biosciences rose 11.09%. AC Immune fell 5.84%, LENZ Therapeutics fell 6.51%, and Cullinan Oncology LLC fell 8.82%Wallstreetcn·Nov 25, 2025 at 09:27 PMPSNL-0.66%SPRY-7.65%
